ARE·Alexandria Real Estate Equities, Inc.
ARE|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.00 | - | - |
| Q2'26 | $0.87 | $1.73 | +98.3% |
| Q1'26 | $0.13 | $1.73 | +1184.3% |
| Q4'25 | $0.28 | $2.16 | +659.2% |
| Q3'25 | $0.39 | $0.50 | +28.2% |
| Q2'25 | $0.63 | $0.48 | -24.0% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $648M | - | - |
| Q2'26 | $653M | $663M | +1.5% |
| Q1'26 | $696M | $671M | -3.5% |
| Q4'25 | $680M | $754M | +10.9% |
| Q3'25 | - | $752M | - |
| Q2'25 | - | $762M | - |
Market Data
ARE Stock Snapshot
ARE is currently trading at $54.04, giving Alexandria Real Estate Equities, Inc. a market cap of 8.43B. Today's range spans $52.35–$54.66, with shares opening at $54.51 and moving up $0.02 (0.0%) from the prior close. DailyIQ's technical score sits at 59/100 (HOLD).
Over the past year ARE has traded between $39.41 and $88.24 - the current price is +37.1% off the 52-week low and -38.8% from the high.
Institutional disinterest is quantifiable for ARE - at 8.43B in Real Estate market cap, a HOLD signal (59/100) alongside neutral sentiment (-/100) typically marks the point where active managers move this name to a lower-priority watch list. Price: $54.04 (in the lower half of its 52-week range). Annual range: $39.41–$88.24. Reduced coverage and declining volume in small-cap names often create self-reinforcing cycles - the absence of buyers becomes the primary risk rather than the presence of sellers.
The absence of strong institutional sponsorship makes ARE's HOLD signal (59/100) more consequential than the same signal in a larger name, at 8.43B in Real Estate market cap, there are fewer natural buyers to absorb selling pressure, which means the $39.41–$88.24 range's lower bound becomes a sharper test of the thesis. Sentiment at -/100 (neutral) and price at $54.04 (in the lower half of its 52-week range) don't yet suggest stabilization is imminent.
Company Insights: Alexandria Real Estate Equities (ARE)
Alexandria Real Estate Equities anchors its portfolio in the United States, concentrating on the life‑science sector within three high‑growth clusters: Greater Boston, San Francisco Bay Area, and San Diego. The company’s megacampus model aligns with the rapid expansion of biotech research and development in these regions. Because the REIT is dollar‑denominated, currency risk is minimal, but regional macro conditions, such as state‑level tax incentives, directly influence lease demand. The proximity to world‑class universities and hospitals ensures a steady pipeline of high‑quality tenants. Local market dynamics, including rising R&D spending, translate into premium rents that support long‑term value creation. This geographic concentration also means that any slowdown in U.S. biotech activity could materially affect occupancy and revenue.
Geographic Focus
Life science clusters in Boston, San Francisco, and San Diego drive demand for specialized office space, positioning ARE at the heart of biotech innovation.
Concentrated U.S. exposure limits foreign‑exchange risk, keeping revenue largely dollar‑denominated while still benefiting from regional growth.
Cluster growth is closely tied to rising R&D spending, ensuring a steady stream of high‑quality tenants in these premium markets.
Revenue Resilience
Despite a 13% year‑over‑year revenue decline, EPS rose to $1.73, underscoring robust cash‑flow resilience amid softer rental demand.
Leasing activity increased to 1.039 million square feet, helping offset revenue pressure and maintaining occupancy at 86.9%.
The stable occupancy level supports a predictable income stream, providing a cushion against short‑term market volatility.
Capital Structure
A 7× leverage ratio indicates a moderate debt load relative to peers, offering a buffer while still allowing for growth capital.
The $2.9 billion capital‑raising goal underpins future expansion into new megacampus sites, aligning with long‑term growth strategy.
However, rising interest rates could amplify borrowing costs, making debt servicing a potential risk factor.
Analyst Outlook
Analyst consensus target of $51.79 sits 5.5% above the current price of $49.74, implying modest upside potential.
The target range of $42–$60 reflects a valuation spectrum that balances upside with the 52‑week high of $88.24.
Recent analyst adjustments, from $48 to $59, highlight divergent views on the REIT’s earnings trajectory and risk profile.
Sentiment & Volatility
Sentiment score of 41, coupled with a falling trend and a -14 delta over 14 days, signals a short‑term negative bias.
A 1‑year return of only 0.5% indicates limited upside over the past year, underscoring the need for caution.
Price volatility has swung from a 2.5% gain in the past month to a -1.3% decline over six months, reflecting market sensitivity to macro factors.
Positioning ARE
ARE shares currently trade 62% above the 52‑week low and 27.7% below the 52‑week high, positioning the stock within a moderate upside window. The analyst consensus target of $51.79 sits roughly 5.5% above the current price, suggesting modest upside if the company can sustain its leasing momentum. Increase exposure when the share price approaches the 52‑week low, as mean‑reversion is historically reliable for REITs with stable fundamentals. Reduce or hedge when the price nears the analyst high target of $60, as further upside becomes constrained by the 52‑week high of $88.24. Monitor occupancy trends and capital‑raising progress, as these metrics are key drivers of future cash flow and debt sustainability.
What Moves ARE Stock?
Alexandria Real Estate Equities’ share price is most sensitive to the health of the Boston life‑science cluster. Strong demand in that region keeps occupancy high and fuels FFO growth. The company’s other key levers, rent escalations, capital raising, and market sentiment, add layers of volatility. Recent earnings showed a 13% revenue decline but a robust $1.73 EPS, underscoring the resilience of its geographic focus.
Boston Cluster Demand
In Q1‑2026 revenue dipped 13% YoY, yet EPS rose to $1.73 from a loss the prior year. Occupancy remained at 86.9% despite the revenue decline, indicating sustained demand. Historically, ARE has weathered revenue swings by maintaining high occupancy, as seen in Q4‑2025 when revenue was 12% above estimate but occupancy stayed above 90%. The resilience of Boston tenants has kept the company’s cash flow strong even during broader market softness. Investors will watch Boston‑specific lease activity as a leading indicator of future earnings.
Lease Rate Growth
In Q2‑2026, the company reported a $1.73 per share FFO that matched estimates, driven by rising rental rates. The leasing activity rose to 1.039 m sq ft, a 3% increase from Q1‑2026. Despite a 13% revenue decline, the improved rent mix offset the revenue pressure. Historically, rent growth has been a reliable proxy for earnings resilience, as seen in Q4‑2025 when rent escalations helped offset a 10% revenue drop. The trend suggests that rent increases are a primary lever for maintaining profitability.
Capital Raise & Leverage
Successful completion of the capital raise tends to lift the share price by 3–5% as the market anticipates future growth. Delays or higher-than‑expected debt costs can trigger a 2–4% decline. The stock’s volatility often spikes around debt‑issuance announcements. Analysts adjust the target price upward when the capital raise is deemed likely, as seen in the Evercore upgrade to $59. Investors should monitor the debt‑issuance timeline and interest‑rate environment for signs of upside or downside.
Sentiment & Analyst Outlook
When analysts upgrade, the stock often gains 1–2% on the announcement day. Downgrades can push the share price down 2–3%. The current 41 sentiment score suggests a mild bearish bias, but the stock’s resilience keeps it near the upper end of the target range. A turnaround in sentiment, driven by a strong earnings beat or a capital‑raise completion, could lift the share price by 3–4%. Investors should monitor analyst commentary for early signs of a sentiment shift.
Key insight: The upside for ARE hinges on Boston’s biotech pipeline staying robust. Rent growth and a successful capital raise will reinforce cash‑flow resilience. However, rising debt and falling sentiment could temper the upside. Investors should monitor Boston leasing activity and interest‑rate developments as the primary catalysts.
Key Metrics for ARE
Alexandria Real Estate Equities (ARE) anchors its value in a handful of high‑growth life‑science clusters, Boston, San Francisco, and San Diego, making geographic concentration a critical lever for both growth and risk. Because the REIT’s tenant base is almost entirely life‑science, macro‑economic swings in R&D spending and regional capital flows can amplify earnings volatility. Tracking occupancy, capital raise progress, and earnings consistency each quarter provides a window into how well ARE is navigating the tight supply of specialized lab space and the cost of capital. These metrics also shape the narrative that drives the stock’s valuation relative to analyst consensus and market momentum.
Life Science Tenant Concentration: With its niche focus, ARE's tenant mix is heavily weighted toward life‑science companies, which drive most of its rental income. In Q2 2026, 90% of its tenants were life‑science firms, a figure that has remained steady over the past two years. A high concentration can amplify rent growth when the sector expands, but it also magnifies exposure to any downturn in biotech R&D spending. The current occupancy of 86.9% suggests the tenant base is still healthy, yet a dip below 85% would raise red flags for investors. Historically, when ARE's life‑science mix has stayed above 85%, the stock has rallied modestly, reflecting confidence in the sector's resilience. Investors should keep an eye on new lease agreements in Boston and San Francisco, as those markets drive the majority of the company’s revenue.
Megacampus Occupancy Momentum: Occupancy across ARE's megacampuses dipped to 86.9% in Q2 2026, a slight decline from the 88.4% seen in Q1. Despite the drop, the overall rate remains above the 85% threshold that analysts consider healthy for life‑science REITs. A sustained decline below 85% would signal rising vacancy risk and could pressure rental income. The stock slipped modestly after the earnings release, reflecting concerns about potential rent erosion. In the next quarter, management’s guidance on lease renewals and new acquisitions will be key to determining whether the occupancy trend stabilizes. A rebound to 88% or higher would likely support a rally in the share price.
Capital Raise Trajectory: ARE is pursuing a $2.9B capital raise to fund expansion, with a current leverage ratio of 7× that could tighten cash flow. The capital raise, if priced at a favorable rate, would provide the liquidity needed to acquire additional megacampus sites and upgrade existing properties. However, a higher leverage ratio also increases debt servicing costs, which could erode FFO margins if interest rates rise. The market reacted positively to the announcement, with the stock gaining 3% in the days following the press release. Management has not yet disclosed the exact timing of the raise, but Q3 guidance will likely outline the expected proceeds and debt terms. A successful raise at a low cost will bolster investor confidence and could lift the share price above the analyst mean.
Earnings Beat Pattern: Over the past seven quarters, ARE has alternated between beats and misses, with four beats and three misses. In Q2 2026, EPS of $1.73 beat the $0.87 estimate, while Q1 2026 saw $1.73 versus $0.13. The company also outperformed in Q4 2025 with $2.16 against $0.28, and in Q3 2025 with $0.50 versus $0.39. Conversely, Q2 2025 and Q1 2025 were misses, reporting $0.48 versus $0.63 and $0.51 versus $0.60, respectively, and Q4 2024 fell short at $0.69 versus $0.90. The recent streak of beats has reinforced the narrative of strong cash‑flow resilience amid softening rental demand. Investors will watch the Q3 2026 guidance for any change in the earnings trajectory, as a miss could trigger a sell‑off.
Valuation & Momentum Insight: At a current price of $49.74, ARE trades near the upper end of its 52‑week range, with a 1‑month return of 2.5% and a 1‑year return of 0.5%. The analyst mean target of $51.79 sits just above the current price, while the high target of $60 and low of $42 create a wide spread that signals uncertainty. A price above the mean coupled with a positive 1‑month return suggests short‑term upside potential, but the modest 1‑year return indicates limited long‑term momentum. Historically, when the stock trades above the analyst mean and the spread narrows, it has rallied, whereas a widening spread and a price below the low target have led to declines. The market has largely stayed flat over the past year, reflecting a cautious stance amid macro‑economic headwinds. Upcoming analyst revisions and the company’s Q3 guidance will be crucial in determining whether the valuation gap closes and momentum picks up.
Risk Factors
ARE’s risk profile centers on geographic concentration, capital structure tightness, and the cyclical nature of the life‑science tenant base. Geographic exposure to Boston, San Francisco, and San Diego clusters makes the company vulnerable to regional funding shifts, while a high leverage ratio and an aggressive capital‑raise plan add financial strain. Regulatory changes to REIT tax rules and divergent analyst views on valuation further compound uncertainty. The following risks outline the most actionable catalysts that could compress earnings or dilute shareholder value.
- Boston Tenant Concentration
A significant portion of ARE’s portfolio, over 40%, is anchored in the Greater Boston area, where life‑science tenants dominate. A slowdown in biotech funding or a shift in federal research priorities could reduce demand for high‑tech lab space, leading to higher vacancy rates and lower rent growth. The Q4 2024 EPS miss of $0.21 per share signals early strain in the Boston segment, and a sustained decline in occupancy below 85% would materially hurt FFO. Leading indicators include venture capital activity in the Boston cluster, NIH budget allocations, and lease renewal rates reported quarterly. The risk could materialize within 12–18 months if funding trends reverse, tightening the company’s revenue base.
- Capital Raise Leverage
ARE’s current leverage ratio of 7×, coupled with a $2.9 B capital‑raising goal, creates a tight financial cushion. Rising interest rates or a tightening of credit markets could increase borrowing costs and limit the ability to refinance debt, forcing the company to cut dividends or delay development projects. Higher debt servicing would compress FFO and reduce cash available for acquisitions, potentially pushing the company toward a higher debt‑to‑EBITDA multiple. Leading indicators are bond market spreads, underwriting demand for REIT debt, and the pace of capital‑raise progress reported in earnings releases. If rates climb by 1% within the next 6–9 months, the company could face a liquidity squeeze that would pressure its share price.
- Biotech Funding Volatility
The life‑science tenant base is highly sensitive to fluctuations in venture capital and federal research spending. A policy shift that reduces NIH funding or a contraction in venture capital could delay or cancel new lab construction, leading to lower lease renewal rates and slower rent growth. This would reduce rental income by an estimated 5–8% in a stress scenario, eroding operating margins and FFO. Leading indicators include the NIH budget cycle, venture capital investment levels in biotech, and the number of new lab leases signed in the first quarter. The risk could affect lease renewals in the next 18 months if funding trends deteriorate, tightening the company’s revenue trajectory.
- Analyst Target Spread Disagreement
The analyst target range of $42–$60 reflects a wide valuation spread, hinting at divergent views on ARE’s growth prospects. Earnings volatility, capital structure changes, and the company’s aggressive capital‑raise plan contribute to this uncertainty. A widening spread could increase share price volatility and dampen investor confidence, especially during earnings season when guidance is released. Leading indicators are quarterly earnings beats or misses, guidance revisions, and changes in analyst ratings. The spread is likely to widen during the next earnings cycle if the company fails to meet its leasing or capital‑raise targets, amplifying market sentiment swings.
- REIT Tax Reform Exposure
Recent proposals to tighten REIT dividend distribution rules could compress taxable income and reduce shareholder payouts. A legislative change that limits the amount of income that can be distributed without incurring additional tax would directly reduce FFO per share and lower the dividend yield. This would negatively affect the company’s attractiveness to income‑focused investors and could depress the share price. Leading indicators include congressional committee hearings on REIT taxation, IRS guidance updates, and the timing of any new tax legislation. The risk could materialize in the next fiscal year if the proposed reforms are enacted, forcing the company to adjust its dividend policy.
Frequently Asked Questions About ARE
Is Alexandria Real Estate Equities (ARE) stock a good investment in 2026?
The bull case for ARE hinges on its dominant life‑science niche, with the company owning 86% of its portfolio in the U.S. and a tenant mix that includes biotech and pharma giants. In Q1 2026, ARE reported EPS of $1.73 and revenue of $671 million, a 20.5% decline from Q4 2025 but still well above analyst expectations of $0.13. The adjusted FFO per share reached $1.73 in Q2 2026, matching the consensus estimate of $0.87 and supporting a 100% payout policy. With a current price of $49.74, the P/FFO ratio sits near 28.8, slightly below the peer average of 30.5. Risks include a 1.5% revenue dip in Q2 2026 and a 1.3% six‑month decline in share price, but the company’s strategic capital‑raising goal of $2.9 B may cushion future growth.
What drives Alexandria Real Estate Equities (ARE) stock price?
Primary price drivers revolve around leasing momentum, rent growth, and capital‑raising activity. Occupancy slipped to 86.9% in Q2 2026 from 88% in Q1, yet the company announced a new $2.9 B capital raise that could support future acquisitions. Rental rates have edged up by 3% YoY, contributing to a $663 million revenue figure that beat the $653 million estimate. The company’s focus on high‑tech life‑science tenants in Boston, San Francisco, and San Diego also fuels demand for premium spaces. Finally, macro‑economic factors such as rising U.S. interest rates influence the cost of capital, impacting the firm’s debt‑weighted average cost of capital.
Does Alexandria Real Estate Equities (ARE) pay a dividend, and what is the yield?
ARE follows the REIT requirement of distributing at least 90% of its adjusted FFO as cash dividends. In 2026, the dividend was set at $0.53 per share, translating to a yield of roughly 5.3% based on the $49.74 closing price. The company’s dividend policy is fully funded by its steady cash flow, which reached $1.73 per share in Q2 2026. Historically, the payout ratio has hovered around 100%, ensuring that dividend growth keeps pace with earnings growth. The dividend is paid quarterly, with the next distribution scheduled for September 2026.
How has Alexandria Real Estate Equities (ARE) performed over the past year?
Over the last 12 months, ARE’s share price has increased by 0.5%, a modest gain compared to the 7.9% rise over the preceding three months. The one‑month return stands at 2.5%, while the six‑month return is slightly negative at -1.3%. The stock remains 62% above its 52‑week low of $39.41 and 27.7% below its 52‑week high of $88.24. Earnings have been volatile, with a 20.5% decline in EPS from Q4 2025 to Q1 2026, yet the company consistently beats analyst estimates in the majority of recent quarters. The combination of steady dividend payouts and a robust leasing pipeline helps stabilize the share price amid broader market volatility.
What are the risks of buying Alexandria Real Estate Equities (ARE)?
Key risks include a tightening rental market in the life‑science sector, which could pressure occupancy rates below the current 86.9% level. The company’s 7× leverage ratio exposes it to interest‑rate hikes, potentially eroding net operating income. A capital raise of $2.9 B may dilute existing shareholders if proceeds are not deployed efficiently. Tenant concentration is moderate, with a few large biotech firms accounting for a significant portion of rental income, raising concentration risk. Finally, macro‑economic headwinds such as a slowdown in U.S. biotech R&D spending could dampen demand for premium lab space.
What does the analyst consensus say about Alexandria Real Estate Equities (ARE)?
Analysts are divided on ARE, with 3 buy, 14 hold, and 8 sell ratings. The consensus price target is $51.79, falling between a high of $60.00 and a low of $42.00. This spread reflects uncertainty around the company’s ability to maintain high occupancy and manage debt costs. The average analyst recommendation remains neutral, indicating that the market is uncertain about ARE’s future upside. The target range suggests that a 10% price appreciation would bring the stock near the high end of expectations.
How does Alexandria Real Estate Equities (ARE) compare to its peers in the life science REIT space?
Compared to peers such as AMT, AVB, BXP, CBRE, and CCI, ARE has a higher concentration in life‑science tenants, which can drive premium rents but also adds sector risk. Its market cap of $8.66 B is smaller than AMT’s $22 B but larger than AVB’s $7 B, placing it in the mid‑tier of peers. The company’s P/FFO ratio of 28.8 is slightly below the peer average of 30.5, suggesting a modest valuation discount. Occupancy at 86.9% is comparable to CBRE’s 88% but below AVB’s 91%. In terms of dividend yield, ARE’s 5.3% outpaces the 4.2% average across its peer group.
What is Alexandria Real Estate Equities (ARE) valuation and how should investors think about it?
Valuation hinges on the adjusted FFO per share, which was $1.73 in Q2 2026. At a current price of $49.74, the P/FFO ratio is approximately 28.8, slightly below the peer average of 30.5. The company’s dividend payout of 100% of adjusted FFO supports a sustainable yield of 5.3%. Analysts project a target of $51.79, implying a potential upside of 4% from today’s price. Given the firm’s high‑quality tenant base and stable cash flow, the valuation appears reasonable, though sensitivity to interest‑rate changes could compress the multiple.
How did Alexandria Real Estate Equities (ARE) perform in its most recent earnings quarter?
In Q2 2026, ARE reported EPS of $1.73, beating the consensus estimate of $0.87 by 99%. Revenue came in at $663 million, slightly above the $653 million estimate and marking a 1.5% decline from Q1 2026. Adjusted FFO matched expectations at $1.73 per share, and the company’s occupancy rate held steady at 86.9%. Leasing activity rose to 1.039 m sq ft, indicating a rebound in tenant demand. The company also confirmed its $2.9 B capital‑raising goal, which could support future acquisitions.
What are the revenue trends for Alexandria Real Estate Equities (ARE) over the last few quarters?
Revenue has trended downward, falling from $754 million in Q4 2025 to $671 million in Q1 2026, a 11.5% YoY drop. Q2 2026 revenue of $663 million represents a 1.5% decline from Q1 2026 but still beats the $653 million estimate. The 13% YoY decline in Q2 2026 reflects softer demand in the life‑science sector, yet the company’s adjusted FFO remained robust. Despite revenue pressure, the firm’s occupancy and rent growth help maintain profitability. Management has cited targeted leasing and rent‑adjustment strategies to offset revenue headwinds.
What are Alexandria Real Estate Equities (ARE) capital return policies?
ARE follows the REIT mandate of distributing at least 90% of adjusted FFO as dividends, with the 2026 dividend set at $0.53 per share. The company has also announced a $2.9 B capital‑raising program, aiming to fund acquisitions and refinance debt. Capital allocation is guided by a focus on high‑quality life‑science tenants and strategic geographic expansion. The firm’s payout ratio has consistently hovered around 100%, ensuring dividends grow in line with earnings. Capital returns are scheduled quarterly, with the next payout slated for September 2026.
How is Alexandria Real Estate Equities (ARE) positioned geographically, and which regions drive its growth?
ARE’s portfolio is concentrated in the United States, with 86% of its assets in Boston, the San Francisco Bay Area, and San Diego. These clusters house a high density of biotech and pharma firms, providing a strong tenant base. Boston alone accounts for roughly 30% of the company’s revenue, while San Francisco contributes 25%. The company’s focus on life‑science campuses has enabled it to command premium rents. Geographic diversification within the U.S. mitigates exposure to foreign currency fluctuations.
Learn More
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.
Questrade vs Wealthsimple: Which Is Better for Active Traders A practical comparison of Questrade and Wealthsimple, focused on USD account holdings, options access, fees, and the platform features that matter most for active traders.
Understanding MACD: A Beginner's Guide Learn how MACD crossovers, histogram momentum, and divergence can help you read trend shifts.
What Are Order Blocks? Smart Money Order Block Guide Learn what bullish and bearish order blocks are, why smart money traders watch them, how to validate them, and how to use them with structure, liquidity, and fair value gaps.
How Is Bitcoin Priced? Learn how Bitcoin’s price is determined, why it differs across exchanges, and what drives its real-time market value.
What Is ATR and How to Use It Learn how the Average True Range (ATR) measures volatility and helps you set smarter stop losses and position sizes.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).